The Relationship Between Thyroid Peroxidase Antibody and Differentiated Thyroid Cancer: a Systematic Review and Meta-analysis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Mar 13

PMID 38476675

Authors

Haonan Zhang

Lijun Tian

Xichang Wang

Xiaoguang Shi

Affiliations

Soon will be listed here.

Abstract

Background: Thyroglobulin antibody (TgAb) has been found to be associated with the occurrence and development of differentiated thyroid cancer (DTC) for several years, but there is still controversy over whether thyroid peroxidase antibody (TPOAb) is related to differentiated thyroid cancer.

Methods: We scrutinized relevant studies published up to July 2023 across four major databases including PubMed, Embase, Cochrane Library, and Web of Science, to examine the association between TPOAb and DTC. Clinical outcome measures include the incidence of DTC, tumor size, extrathyroidal invasion, lymph node metastasis, multifocality, recurrence and bilaterality.

Results: 12 original studies were included, involving a total of 20,330 subjects. Our analysis of the included studies revealed that TPOAb+ individuals exhibited a higher risk of developing DTC (OR=1.57 [95% CI: 1.00-2.45], p=0.049) than TPOAb- individuals. Furthermore, TPOAb+ DTC patients were more prone to present with bilateral (OR=1.40 [95% CI: 1.21-1.62], p<0.00001) and multifocal (OR=1.40 [95% CI: 1.23-1.60], p<0.00001) tumors than TPOAb- patients. Sensitivity analysis indicated a high sensitivity for these three findings. No significant differences in the risk of extrathyroidal extension and lymph node metastasis, recurrence rate, tumor size, were observed between TPOAb+ and TPOAb- DTC patients.

Conclusion: The presence of TPOAb is correlated with an increase prevalence of DTC. However, its effectiveness as a prognostic marker for DTC patients warrants further investigation.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023448824.

Citing Articles

A comprehensive prediction model for central lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis: BRAF may not be a valuable predictor.

Chen Y, Zhao S, Zhang Z, Chen Z, Jiang B, An M Front Endocrinol (Lausanne). 2024; 15:1429382.

PMID: 39363900 PMC: 11446765. DOI: 10.3389/fendo.2024.1429382.

References

Peng X, Zhu X, Cheng F, Zhou B, Zhu X, Zhu L . Correlation between thyroid autoantibodies and the risk of thyroid papillary carcinoma. Gland Surg. 2020; 9(4):950-955. PMC: 7475372. DOI: 10.21037/gs-20-445. View

Feldt-Rasmussen U . Hashimoto's thyroiditis as a risk factor for thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2020; 27(5):364-371. DOI: 10.1097/MED.0000000000000570. View

Qin J, Yu Z, Guan H, Shi L, Liu Y, Zhao N . High Thyroglobulin Antibody Levels Increase the Risk of Differentiated Thyroid Carcinoma. Dis Markers. 2015; 2015:648670. PMC: 4639663. DOI: 10.1155/2015/648670. View

Xu S, Huang H, Qian J, Liu Y, Huang Y, Wang X . Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes. JAMA Netw Open. 2021; 4(7):e2118526. PMC: 8317012. DOI: 10.1001/jamanetworkopen.2021.18526. View

Yip L, Sosa J . Molecular-Directed Treatment of Differentiated Thyroid Cancer: Advances in Diagnosis and Treatment. JAMA Surg. 2016; 151(7):663-70. DOI: 10.1001/jamasurg.2016.0825. View

Soyluk O, Boztepe H, Aral F, Alagol F, Ozbey N . Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial.... Thyroid. 2011; 21(12):1301-8. DOI: 10.1089/thy.2011.0122. View

Ehlers M, Schott M . Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?. Trends Endocrinol Metab. 2014; 25(12):656-64. DOI: 10.1016/j.tem.2014.09.001. View

Schlumberger M, Leboulleux S . Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2020; 17(3):176-188. DOI: 10.1038/s41574-020-00448-z. View

Boi F, Lai M, Marziani B, Minerba L, Faa G, Mariotti S . High prevalence of suspicious cytology in thyroid nodules associated with positive thyroid autoantibodies. Eur J Endocrinol. 2005; 153(5):637-42. DOI: 10.1530/eje.1.02020. View

10.

Selek A, Cetinarslan B, Tarkun I, Canturk Z, Ustuner B, Akyay Z . Thyroid autoimmunity: is really associated with papillary thyroid carcinoma?. Eur Arch Otorhinolaryngol. 2016; 274(3):1677-1681. DOI: 10.1007/s00405-016-4414-6. View

11.

Vasileiadis I, Boutzios G, Charitoudis G, Koukoulioti E, Karatzas T . Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. Ann Surg Oncol. 2014; 21(8):2725-32. DOI: 10.1245/s10434-014-3593-x. View

12.

Baloch Z, Asa S, Barletta J, Ghossein R, Juhlin C, Jung C . Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol. 2022; 33(1):27-63. DOI: 10.1007/s12022-022-09707-3. View

13.

Pani F, Caria P, Yasuda Y, Makoto M, Mariotti S, Leenhardt L . The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis. Cancers (Basel). 2022; 14(17). PMC: 9454449. DOI: 10.3390/cancers14174287. View

14.

Wang Y, Zheng J, Hu X, Chang Q, Qiao Y, Yao X . A retrospective study of papillary thyroid carcinoma: Hashimoto's thyroiditis as a protective biomarker for lymph node metastasis. Eur J Surg Oncol. 2022; 49(3):560-567. DOI: 10.1016/j.ejso.2022.11.014. View

15.

Wang W, Wen L, Chen S, Su X, Mao Z, Ding Y . Preoperative Thyroid Peroxidase Antibody Predicts Recurrence in Papillary Thyroid Carcinoma: A Consecutive Study With 5,770 Cases. Front Oncol. 2022; 12:881024. PMC: 9124958. DOI: 10.3389/fonc.2022.881024. View

16.

Huang D, Zhi J, Zhang J, Qin X, Zhao J, Zheng X . Relationship Between Thyroid Autoantibodies and Recurrence of Papillary Thyroid Carcinoma in Children and Adolescents. Front Oncol. 2022; 12:883591. PMC: 9213685. DOI: 10.3389/fonc.2022.883591. View

17.

Jiskra J, Barkmanova J, Limanova Z, Lanska V, Smutek D, Potlukova E . Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival. Oncol Rep. 2007; 18(6):1603-11. View

18.

Xu J, Ding K, Mu L, Huang J, Ye F, Peng Y . Hashimoto's Thyroiditis: A "Double-Edged Sword" in Thyroid Carcinoma. Front Endocrinol (Lausanne). 2022; 13:801925. PMC: 8907134. DOI: 10.3389/fendo.2022.801925. View

19.

Viola N, Agate L, Caprio S, Lorusso L, Brancatella A, Ricci D . Thyroid autoimmunity, thyroglobulin autoantibodies, and thyroid cancer prognosis. Endocr Relat Cancer. 2023; 30(7). DOI: 10.1530/ERC-23-0042. View

20.

Barres B, Kelly A, Kwiatkowski F, Batisse-Lignier M, Fouilhoux G, Aubert B . Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers. J Clin Endocrinol Metab. 2019; 104(8):3462-3472. DOI: 10.1210/jc.2018-02680. View